logo

MDXH

MDxHealth·NASDAQ
--
--(--)
--
--(--)
2.19 / 10
Underperform

Comprehensive fundamental analysis rates MDxHealth at 2.2/10. Strengths include positive Profit-MV and Net income-Revenue factors, but significant headwinds come from Revenue-MV and PB-ROE metrics. Historical back-tests show limited one-month returns (e.g., 7.95% for Profit-MV), indicating sub-par performance relative to peers and a constrained investment case.

Fundamental(2.19)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.26
Score1/3
Weight11.03%
1M Return5.63%
Inventory turnover ratio
Value5.50
Score3/3
Weight10.11%
1M Return5.89%
Gross profit margin (%)
Value65.04
Score2/3
Weight2.45%
1M Return1.40%
Profit-MV
Value0.47
Score2/3
Weight15.44%
1M Return7.95%
Net income-Revenue
Value-0.15
Score2/3
Weight15.65%
1M Return8.04%
PB-ROE
Value1.19
Score0/3
Weight7.92%
1M Return4.05%
Current assets turnover ratio
Value1.25
Score1/3
Weight0.43%
1M Return0.27%
Fixed assets turnover ratio
Value16.00
Score2/3
Weight0.05%
1M Return0.03%
Asset-MV
Value-0.51
Score1/3
Weight21.62%
1M Return9.84%
Cash-MV
Value-0.07
Score2/3
Weight15.30%
1M Return7.78%
Is MDXH undervalued or overvalued?
  • MDXH scores 2.19/10 on fundamentals and holds a Premium valuation at present. Backed by its -747.67% ROE, -30.50% net margin, -5.77 P/E ratio, -21.94 P/B ratio, and 66.01% earnings growth, these metrics solidify its Underperform investment rating.